Royalty Pharma plc 8-K Report: Key Insights from December 31, 2024 Filing
Based on the provided section of the financial report, here are the key pieces of information and insights extracted:
- Company Information:
- Name: Royalty Pharma plc
- CIK Number: 0001802768
- SEC File Number: 001-39329
- Address: 110 East 59th Street, New York, NY 10022
- Phone Number: (212) 883-0200
- Security Information:
- Security Type: Class A Ordinary Shares
- Par Value: $0.0001 per share
- Ticker Symbol: RPRX
- Exchange: NASDAQ
- Filing Details:
- Filing Type: 8-K
- Filing Date: December 31, 2024
- Period of Report:
- Reporting Period: The report covers a single day, December 31, 2024.
- XML and XBRL Information:
- The report is structured in XBRL (eXtensible Business Reporting Language), which is a standardized format used for reporting financial data.
Insights:
- The report is likely a current report (Form 8-K), which is used to disclose major events that shareholders should know about, suggesting that this filing could contain significant information or developments concerning Royalty Pharma.
- The specific date of the report indicates a focus on end-of-year activities or events that occurred on that date, which may impact financial performance or strategic direction.
- The company's listing on NASDAQ under the ticker RPRX suggests it is publicly traded and subject to regulatory requirements, including timely disclosures to investors.
Overall, this information is essential for investors and analysts monitoring Royalty Pharma's performance and compliance with SEC regulations.